Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance

Cancer. 2020 Jul 1;126(13):2986-2990. doi: 10.1002/cncr.32821. Epub 2020 Apr 22.

Abstract

Background: Adoption of prostate magnetic resonance imaging (MRI) before biopsy is based on evidence demonstrating superior detection of clinically significant prostate cancer on biopsy. Whether this is due to the detection of otherwise occult higher grade cancers or preferential sampling of higher grade areas within an otherwise low-grade cancer is unknown.

Methods: To distinguish these two possibilities, this study examined the effect of prebiopsy MRI on the rate of pathologic upgrading and downgrading at prostatectomy in Surveillance, Epidemiology, and End Results-Medicare linked data from 2010 to 2015. Logistic regression was performed to assess the effect of MRI use on the Gleason grade change between biopsy and prostatectomy.

Results: Among biopsy-naive men, those who underwent prebiopsy MRI had higher odds of downgrading at prostatectomy (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.05-1.66). In contrast, the odds of upgrading were significantly lower for men who underwent prebiopsy MRI (OR, 0.78; 95% CI, 0.61-0.99). Limitations included a low overall rate of MRI-utilization prior to biopsy and an inability to distinguish between template, software-assisted and cognitive fusion biopsy.

Conclusions: Prebiopsy MRI is associated with both oversampling of higher grade areas, which results in downgrading at prostatectomy, and the detection of otherwise occult higher grade lesions, which results in less upgrading at prostatectomy.

Keywords: image-guided biopsy; magnetic resonance imaging; prostatic neoplasms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Humans
  • Image-Guided Biopsy / methods*
  • Logistic Models
  • Magnetic Resonance Imaging*
  • Male
  • Neoplasm Grading
  • Odds Ratio
  • Preoperative Period
  • Prostate / diagnostic imaging
  • Prostate / pathology*
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / pathology*
  • SEER Program

Substances

  • Prostate-Specific Antigen